Preselection of subjects for therapeutic treatment based on hypoxic status
AssigneeSynta Pharmaceuticals Corp.
InventorsRonald K. Blackman, Vojo Vukovic
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an agent to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.
Claims24
A method of treating a subject having cancer comprising:
- administering an agent selected from the group consisting of bevacizumab, STA-9090, temsirolimus, erlotinib, sorafenib, sunitinib, PTK787, BEZ235, XL765, pazopanib, cediranib, and axitinib to the subject, wherein the cancer comprises a tumor with a high level of hypoxia.
A method for identifying a subject for treatment with an agent selected from the group consisting of bevacizumab, STA-9090, temsirolimus, erlotinib, sorafenib, sunitinib, PTK787, BEZ235, XL765, pazopanib, cediranib, and axitinib, comprising:
- determining the level of hypoxia in a tumor from the subject, wherein a high level of hypoxia in the sample indicates the subject is likely to respond to therapy with an agent selected from the group consisting of bevacizumab, STA-9090, temsirolimus, erlotinib, sorafenib, sunitinib, PTK787, BEZ235, XL765, pazopanib, cediranib, and axitinib.
14-15. (canceled)
The method of claim 15, wherein the activity level or expression level of the one or more hypoxia modulated polypeptides are up regulated in the sample.
18-23. (canceled)
A kit for selecting a therapeutic regimen including an agent selected from the group consisting of bevacizumab, STA-9090, temsirolimus, erlotinib, sorafenib, sunitinib, PTK787, BEZ235, XL765, pazopanib, cediranib, and axitinib for the treatment of cancer comprising:
- at least one reagent for determining the level of hypoxia of in a subject sample;
- wherein the level of hypoxia is used to select the treatment regimen including an agent selected from the group consisting of bevacizumab, STA-9090, temsirolimus, erlotinib, sorafenib, sunitinib, PTK787, BEZ235, XL765, pazopanib, cediranib, and axitinib.
26-27. (canceled)
30-46. (canceled)
Dependencies are inferred from the claim text.